

Artrya Management Update

Strengthening leadership team to support next phase of growth

PERTH, Australia, 27 January 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix[®] AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, advises that Richard Jarvis of The CFO Bridge has been appointed Chief Financial Officer effective immediately.

Mr Jarvis' appointment is intended to be transitional, as the Company commences an executive search process with Stanton Chase to appoint a permanent Chief Financial Officer to lead the finance function through the next phase of Artrya's growth.

Mr Jarvis is a Chartered Certified Accountant with more than 25 years' experience in senior finance and accounting roles, including 18 years as Chief Financial Officer of ASX-listed companies across a range of sectors. He brings significant international experience, having operated across multiple jurisdictions.

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

"As Artrya continues to progress its commercialisation strategy and expand its U.S. footprint, we are strengthening the leadership team with experienced executives who bring deep expertise in scaling businesses, driving commercial outcomes, and operating in the U.S. market. The executive search for a CFO who brings that expertise reflects our commitment to ensuring Artrya is well positioned to execute its growth strategy and accelerate the next phase of the Company's development."

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com